Katharina S. Götze

The target landscape of clinical kinase drugs

Susan Klaeger, Stephanie Heinzlmeir, Mathias Wilhelm et al. · Science · 2017 · 871 citations · Full text

Medicine, Oncology, Pharmacology +15

<i>IDH1</i>and<i>IDH2</i>Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With<i>NPM1</i>Mutation Without<i>FLT3</i>Internal Tandem Duplication

Peter Paschka, Richard F. Schlenk, Verena I. Gaidzik et al. · Journal of Clinical Oncology · 2010 · 791 citations

Life Sciences, Genetics, Hematology +16

Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i>–Internal Tandem Duplication Mutation (SORMAIN)

Andreas Burchert, Gesine Bug, Lea Fritz et al. · Journal of Clinical Oncology · 2020 · 551 citations · Full text

Medicine, Hematology, Oncology +15

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 537 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML

Sabine Käyser, Konstanze Döhner, Jürgen Krauter et al. · Blood · 2010 · 485 citations

Medicine, Hematology, Oncology +11